Lacosamide

Vimpat (erlosamide) is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against sodium channel protein type 9 subunit alpha. In addition, it is known to target sodium channel protein type 2 subunit alpha, sodium channel protein type 3 subunit alpha, and sodium channel protein type 10 subunit alpha.